homepagecommon questionsarchiveinfocontacts
forumbulletinfieldsreads

Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event

October 8, 2026 - 08:18

Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event

Celcuity Inc. saw its shares drop 17.3 percent after the company announced two significant developments regarding its breast cancer treatment. The company confirmed that REVTORPYK, also known as gedatolisib, is now commercially available in the United States for eligible patients with HR-positive, HER2-negative advanced breast cancer who do not have a PIK3CA mutation.

Alongside the launch, Celcuity introduced REVTORPYK Support Services, a program designed to help patients and providers navigate access, reimbursement, and financial assistance. The company stated the service aims to reduce barriers to treatment and streamline the process for those seeking the therapy.

In addition to the commercial launch, Celcuity submitted a supplemental New Drug Application to the Food and Drug Administration. If approved, this filing would expand the prescribing label to allow physicians to use REVTORPYK regardless of a patient's PIK3CA tumor status. The submission also includes data intended to support broader clinical use across a larger patient population.

The stock decline suggests investors may have expected different timing or terms around the announcements. Market reaction often reflects concerns about competition, pricing, or the pace of regulatory review. Celcuity has not commented on the share movement. The company continues to work with regulators and payers as it rolls out the treatment and support program. Further updates are expected as the sNDA review progresses.


MORE NEWS

Nasdaq Starts Charging for Financial Crime AI Agents as 850 Customers Sign On

November 22, 2026 - 00:48

Nasdaq Starts Charging for Financial Crime AI Agents as 850 Customers Sign On

Nasdaq is taking a significant step by implementing fees for its artificial intelligence agents designed to combat financial crime. This move comes as the company seeks to expand its offerings in...

Key Insights for Long-Term Investors in Globant

November 21, 2026 - 04:20

Key Insights for Long-Term Investors in Globant

Globant`s recent shift to outcome-based pricing has shown promising results, particularly in its impact on gross margins. This new pricing strategy has already lifted gross margins by approximately...

Docusign to Release Third Quarter Financial Results on December 3, 2026

November 20, 2026 - 02:05

Docusign to Release Third Quarter Financial Results on December 3, 2026

Docusign has announced that it will share its financial results for the third quarter of fiscal 2027 after the U.S. markets close on Thursday, December 3, 2026. Following the release, the company...

Royal Gold Expands Board with Mining Veteran Harry Kenyon-Slaney

November 19, 2026 - 01:35

Royal Gold Expands Board with Mining Veteran Harry Kenyon-Slaney

DENVER, November 18, 2026--Royal Gold has taken a significant step in enhancing its leadership by appointing Harry Kenyon-Slaney to its Board of Directors. Kenyon-Slaney brings a wealth of...

read all news
homepagecommon questionsarchiveinfocontacts

Copyright © 2026 Taxlyf.com

Founded by: Audrey Bellamy

forumbulletinfieldsrecommendationsreads
terms of useyour datacookie info